Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
memo - Magazine of European Medical Oncology
Erschienen in:

01.09.2014 | short review

Aggressive lymphoma at ASH 2013: R-CHOP under attack?

verfasst von: Thomas Nösslinger, MD

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 3/2014

Einloggen, um Zugang zu erhalten

Abstract

Recent clinical data presented at the annual meeting of the American Society of Hematology challenge the predominance of R-CHOP in the first line treatment of diffuse large B cell lymphoma. New therapeutic agents such as lenalidomide and ibrutinib are tested successfully in clinical trials in combination with established therapies. Interesting results from the Austrian non-Hodgkin lymphoma (NHL)-13 trial underline the possible relevance of rituximab maintenance in specific patient subgroups. New data on unfavorable subtypes, such as double hit lymphomas, NHL at risk for central nervous system relapse, and refractory disease with CD30 expression were reported. Finally some promising therapeutic options for the unfavorable subset of extranodal NK/T-cell lymphoma were presented.
Vorheriger Artikel Highlights of the American Society of Hematology Meeting 2013: hemostaseology
Nächster Artikel Myelodysplastic syndromes (MDS)
Literatur
1.
Chiappella A, Franceschetti S, Castellino A, et al. Final results of phase II study of Lenalidomide plus Rituximab-CHOP21 in elderly untreated diffuse large B-Cell lymphoma focusing on the analysis of the cell of origin: REAL07 trial of the Fondazione Italiana Linfomi. Blood (ASH annual meeting abstracts). 2013;122:(abstr 850).
2.
Younes A, Flinn I, Berdeja J, et al. Combining Ibrutinib With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP): updated results from a phase 1b study in treatment-naïve patients with CD20-positive B-cell Non-Hodgkin’s Lymphoma (NHL). Blood (ASH Annual Meeting Abstracts). 2013;122:(abstr 852).
3.
Jaeger U, Trneny M, Melzer H, et al. Rituximab maintenance significantly prolongs Event Free (EFS) and Progression Free Survival (PFS) In male patients with aggressive B-Cell lymphoma in the NHL13 Study. Blood (ASH annual meeting abstracts). 2013;122:(abstr 851).
4.
Jaeger U, Fridrik M, Zeitlinger M, et al. Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response. Haematologica. 2012;97(9):1431–8.
5.
Crump M, Leppae S, Fayad L, et al. A phase III study of Enzastaurin in patients with high-risk diffuse large B cell lymphoma following response to primary treatment, Prelude trial. Blood (ASH annual meeting abstracts). 2013;122:(abstr 371).
6.
Leppae S, Tierens AM, Jorgensen J, et al. Dose-Dense chemoimmunotherapy and early central nervous system prophylaxis for high-risk diffuse large B-Cell lymphoma. –preliminary results from a Nordic phase II study. Blood (ASH annual meeting abstracts). 2013;122:(abstr 849).
7.
Gandhi M, Petrich A, Cassaday R, et al. Impact of induction regimen and consolidative stem cell transplantation in patients with Double Hit Lymphoma (DHL): a large multicenter retrospective analysis. Blood (ASH annual meeting abstracts). 2013;122:(abstr 640).
8.
Xu-Monette Z, Dabaja B, Tzankov A, et al. Radiation therapy significantly improves survival of patients with diffuse large B-Cell lymphoma associated with MYC translocation: a report from the International DLBCL rituximab-CHOP consortium program. Blood (ASH annual meeting abstracts). 2013;122:(abstr 641).
9.
Bartlett N, Sharman J, Oki Y, et al. A phase 2 study of Brentuximab Vedotin in patients with relapsed or refractory CD30-positive non-Hodgkin lymphomas: interim results in patients with DLBCL and other B-Cell lymphomas. Blood (ASH annual meeting abstracts). 2013;122:(abstr 848).
10.
Gao Y, Huang H, QiChun C, et al. Efficacy and safety of pegaspargase with Gemcitabine and Oxaliplatin in patients with treatment-naïve, refractory extranodal natural killer/T-Cell lymphoma: a single-centre experience. Blood (ASH annual meeting abstracts). 2013;122:(abstr 642).
11.
Yamaguchi M, Tobinai K, Oguchi M, et al. Phase I/II study on concurrent chemoradiotherapy for localized nasal NK/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG2011. J Clin Oncol. 2009;27:5594–600.PubMedCrossRef
Metadaten
Titel
Aggressive lymphoma at ASH 2013: R-CHOP under attack?
verfasst von
Thomas Nösslinger, MD
Publikationsdatum
01.09.2014
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 3/2014
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-014-0148-6

Weitere Artikel der Ausgabe 3/2014

ASH 2013: short review on myeloproliferative neoplasms

  • short review

Myelodysplastic syndromes (MDS)

  • short review

Clinicopathological profile of bilateral breast cancer at a tertiary cancer center in South India

  • original report

Importance of intraoperative radiation therapy in the treatment of soft tissue sarcoma: data at hand

  • review

The challenge of soft tissue sarcomas—critical aspects of therapies with curative intent

  • editorial

Surgical aspects in the treatment of retroperitoneal soft tissue sarcomas

  • short review